EMA removes negative note on label of PTC's Duchenne drug; GSK, Akebia win Japan OK for oral anemia drugs
→ PTC Therapeutics $PTCT won conditional approval to market ataluren for Duchenne MD in Europe way back in 2014 — despite the fact that all the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
